Scope
NICE NG141 addresses cellulitis and erysipelas with attention to diagnostic mimics, early deterioration, antimicrobial selection and selected recurrent-disease prophylaxis. This focused summary includes representative adult oral regimens and the major referral rules. It separates routine skin infection from orbital disease, deep infection and sepsis.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Check the diagnosis and infection extent
- Before diagnosing cellulitis or erysipelas, exclude non-infective redness, including reactions to vaccination or insect bites and chronic venous insufficiency. Consider outlining the affected area with a single-use surgical marker; erythema may be harder to see on darker skin. [1]
- Initially consider a swab only when skin is broken and there is penetrating injury, water exposure or infection acquired outside the UK. This is a UK epidemiological distinction; unusual exposure and regional organisms should guide local microbiology assessment. [1]
- Offer antibiotics, considering severity, proximity to the eyes or nose, unusual-pathogen risk, previous swab results and known MRSA status. Manage contributing diabetes, venous insufficiency, eczema or oedema alongside the infection. [1]
Use oral treatment when suitable and reassess deterioration
- Start oral antibiotics when the patient can take them and severity does not require intravenous therapy. If intravenous treatment is used, review by 48 hours and consider switching to oral treatment. [1]
- Explain antibiotic adverse effects and that skin changes may persist after the course ends. Seek medical review for rapid or significant worsening or if improvement has not begun within 2–3 days. [1]
- Reassess systemic illness, pain out of proportion, rapid deterioration or spreading redness or swelling. Some initial spread can occur, but reassessment should consider an alternative diagnosis, a serious complication and prior antibiotic exposure. [1]
- During reassessment, consider a swab if skin is broken and none was obtained. Review available microbiology and, if infection is not improving, change antibiotics according to results, narrowing the spectrum where possible. [1]
Recognize infections needing hospital or specialist care
- Refer to hospital for suspected orbital cellulitis, osteomyelitis, septic arthritis, necrotising fasciitis, sepsis or another serious illness. These situations are not routine outpatient cellulitis. [1]
- Consider hospital referral or specialist advice for severe illness, infection near the eyes or nose, unusual exposures or organisms, lymphangitis, spreading infection despite oral therapy, or inability to take oral antibiotics. Where appropriate, assess local community intravenous options. [1]
Selected prescribing principles and adult regimens
- For adults aged 18 years and over, the first-choice oral regimen is flucloxacillin 500 mg–1 g four times daily for 5–7 days, unless oral treatment is unsuitable or illness is severe. The guideline notes that the higher oral dose was off-label at publication. [1]
- In nonpregnant adults aged 18 years and over with penicillin allergy or unsuitable flucloxacillin, the table includes oral clarithromycin 500 mg twice daily for 5–7 days or doxycycline 200 mg on day one then 100 mg daily for a total 5–7 days. Pregnancy needs its separate macrolide considerations. [1]
- For adults aged 18 years and over with infection near the eyes or nose, NICE lists oral co-amoxiclav 500/125 mg three times daily for 7 days when oral therapy is appropriate. Consider specialist advice because this location carries risk of serious intracranial complications. [1]
- A course up to 14 days may be needed after clinical reassessment, but incomplete normalization of skin at 5–7 days alone is expected and does not establish treatment failure. [1]
- Use the separate paediatric table for people under 18; antibiotic choice for infants under one month requires specialist advice. Check pregnancy, renal and hepatic impairment and current product guidance before applying any regimen. [1]
Restrict prophylaxis to selected recurrent disease
- Do not routinely prescribe prophylactic antibiotics for recurrent cellulitis or erysipelas. Advise patients to seek care if another episode develops. [1]
- Specialists may consider prophylaxis in adults with at least 2 separate episodes in the previous 12 months that were treated in hospital or under specialist advice. Discuss severity, complications, management of underlying conditions, resistance and the patient’s preferences. [1]
- Choose prophylaxis using previous microbiology and antibiotic exposure. Review at least every 6 months, discussing effectiveness, adverse effects, resistance and whether to continue, stop or change. Stop or change prophylaxis if cellulitis recurs and treat the acute infection. [1]
Limitations and use
- This is UK antimicrobial guidance; local Indian susceptibility, availability, allergies, interactions and current prescribing restrictions require assessment. The location- and exposure-specific rules are not a substitute for specialist diagnosis.
- The complete paediatric, intravenous, MRSA, severe-infection and prophylactic dosing tables are not reproduced. Suspected necrotising infection, sepsis or orbital cellulitis needs the appropriate urgent pathway.
- Skin improvement and clinical stability should guide reassessment; the selected summary does not provide a diagnostic test to distinguish every cellulitis mimic.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Cellulitis and erysipelas: antimicrobial prescribing
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 27 September 2019
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.